Qwixel Therapeutics addresses the need to develop therapeutics to treat multiple myeloma (MM), a B cell cancer disease that is not curable.


The anti-CD138 fused with Interferon (IFN) will both directly kill the malignant cells and will help boost the immune system decreasing the possibility of a relapse. The global multiple myeloma treatment market was $21.6 billion in 2022.


IFNs are potent anti-cancer agents. In order to treat cancer effectively, high concentrations of IFN at the tumor must be obtained. Qwixel's goal is to concentrate IFN at the tumor site by fusing it to antibodies that recognize CD138, a protein expressed on the surface of myeloma cells.


  • Potential to cure disease
  • Improved quality of life
  • Increased life expectancy

Development Stage:

  • Pre-clinical

Patents Issued:

  • CD138-Targeted Interferon Demonstrates Potent Apoptotic And Anti-Tumor Activities; US 9,803,021 B2 on 06/04/2015

Select Publications:

Qwixel Therapeutics merged with Nammi Therapeutics in 2021

Back to Top